MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, has signed an exclusive agreement with Teva Pharmaceuticals Ltd. for commercialization of ConfirmMDx for Prostate Cancer and PredictMDx for glioblastoma tests in Israel. ConfirmMDx provides physicians with actionable information that helps improve patient care, particularly the avoidance of unnecessary repeat prostate biopsies.

The PredictMDx test is used to identify glioma patients who have methylation of the MGMT (O6-Methylguanine-DNA Methyltransferase) gene. In clinical studies, these patients have shown the potential to respond better to certain chemotherapeutic drugs.

"This partnership with Teva means that these important tests will now become available to cancer patients in Israel, our second market after the US," said Dr Jan Groen, CEO of MDxHealth. "We are delighted that Teva has agreed to invest its significant commercialization resources into our unique cancer products, expanding access to a new and diverse patient population."

Under the terms of this three-years agreement, Teva Pharmaceuticals Industries will be the exclusive distributor of both tests in Israel. Samples will be sent to MDxHealth's CLIA-registered laboratory in Irvine, California for analysis. Teva will reimburse MDxHealth for all the testing services.

MDxHealth's PredictMDx for Glioblastoma (MGMT) test provides actionable information to oncologists seeking to provide personalized treatment of patients with brain cancer.  The test assesses the methylation status of the MGMT gene, which is crucial to promoting DNA repair.  If the MGMT gene is methylated, cancer patients have shown improved response to alkylating drug therapy.  Studies on thousands of patients have shown that PredictMDx for Glioblastoma can help identify patients that are likely to respond to the most commonly used class of brain cancer drugs (alkylating agents).

MDxHealth is a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment.

Teva Pharmaceuticals Industries Ltd. is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients.